Twice-yearly opioid dependence implant steps closer to the market

California-based Titan Pharmaceuticals, a company focusing on products for CNS disorders, has submitted its 6-month subdermal buprenorphine implant for approval with the FDA for the maintenance treatment of opioid dependence in adults. The submission includes a request for a priority review.

The implant, Probuphine, uses the company's ProNeura delivery system, in which a solid rod is inserted under the skin, normally in the upper arm, and releases the drug continuously. Titan believes that it is the first product designed to deliver 6 months of buprenorphine at a single dose.

This is a major market – there are around 6 million opioid addicts worldwide, including illegal and prescription opioids. Buprenorphine is a standard medication for the treatment of opioid dependence, and the 2011 market for the daily dose formulation was worth around $1.3 billion in the U.S. A sustained release and long-term version could improve compliance, and therefore reduce the impact of addition on addicts, their families and friends, and on society.

In September, an undisclosed potential licensee for Probuphine invested $4.25 million into the company, and has committed further resources to the commercialization of the implant, should it reach the market. The license option expires at the end of December.

- read the press release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…